z-logo
Premium
Sensitivity analysis in non‐inferiority trials with residual inconstancy after covariate adjustment
Author(s) -
Zhang Zhiwei,
Nie Lei,
Soon Guoxing,
Zhang Bo
Publication year - 2014
Publication title -
journal of the royal statistical society: series c (applied statistics)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.205
H-Index - 72
eISSN - 1467-9876
pISSN - 0035-9254
DOI - 10.1111/rssc.12050
Subject(s) - covariate , residual , econometrics , statistics , placebo , sensitivity (control systems) , mathematics , medicine , algorithm , alternative medicine , pathology , electronic engineering , engineering
Summary A major issue in non‐inferiority trials is the controversial assumption of constancy, namely that the active control has the same effect relative to placebo as in previous studies comparing the active control with placebo. The constancy assumption is often in doubt, which has motivated various methods that ‘discount’ the control effect estimate from historical data as well as methods that adjust for imbalances in observed covariates. We develop a new approach to deal with residual inconstancy, i.e. possible violations of the constancy assumption due to imbalances in unmeasured covariates after adjusting for the measured covariates. We characterize the extent of residual inconstancy under a generalized linear model framework and use the results to obtain fully adjusted estimates of the control effect in the current study based on plausible assumptions about an unmeasured covariate. Because such assumptions may be difficult to justify, we propose a sensitivity analysis approach that covers a range of situations. This approach is developed for indirect comparison with placebo and effect retention, and implemented through additive and multiplicative adjustments. The approach proposed is applied to two examples concerning benign prostate hyperplasia and human immunodeficiency virus infection, and evaluated in simulation studies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here